UBS Knock-Out AMGN/ DE000UH93XM0 /
8/30/2024 1:38:01 PM | Chg.0.000 | Bid1:38:01 PM | Ask1:38:01 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.300EUR | 0.00% | 1.300 Bid Size: 25,000 |
1.320 Ask Size: 25,000 |
Amgen Inc | 188.6934 USD | 12/31/2078 | Call |
GlobeNewswire
8/15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
8/12
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
8/8
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/8
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
8/5
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
8/1
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
7/22
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
7/2
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
6/27
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
6/27
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...
GlobeNewswire
6/20
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...